





~1 million patients have used Neulasta® Onpro®

*If, for any reason, you believe you did not receive your full dose of Neulasta® or that your on-body injector is not working correctly, immediately contact your healthcare provider, as an incomplete dose could increase infection risk.


Indication

Neulasta® is a prescription medicine used to help reduce the chance of infection due to a low white blood cell count, in people with certain types of cancer (non-myeloid), who receive anti-cancer medicines (chemotherapy) that can cause fever and low white blood cell count.

Important Safety Information

Do not take Neulasta® if you have had a serious allergic reaction to pegfilgrastim or filgrastim.





Learn how you could pay \$5 or less per dose*

*For eligible commercially insured patients, up to annual limit.

Being diagnosed with cancer can be overwhelming. If your treatment plan includes strong chemotherapy, this guide can help.

On the following pages, you'll learn how Neulasta® can help reduce the risk of infection, and how Neulasta® Onpro® is designed to let you stay at home, without having to return to your doctor for another appointment. Staying at home can also help reduce your risk of exposure to viral infections.

Already using Neulasta® Onpro®? Find practical information about using the product on pages 14-17.

TABLE OF CONTENTS

- 2 Introduction
- 4 Chemo and Your White Blood Cells
- 6 How Neulasta® Works
- 8 Stay Home With Neulasta® Onpro®
- 10 Common Challenges
- 12 Patient Planner
- 14 Your Neulasta® Onpro® Device
- 16 Overview for Using Neulasta® Onpro®
- 18 Fighting the Risk of Infection
- 20 Questions You Can Ask Your Doctor
- 22 What to Expect
- 24 Financial Resources
- 26 Paying for Neulasta® Onpro®
- 28 Things To Know About Neulasta® Onpro®
- 30 Important Safety Information

Important Safety Information

Before you receive Neulasta®, tell your healthcare provider about all of your healthcare conditions, including if you: Have a sickle cell disorder; have had severe skin reactions to acrylic adhesives; are allergic to latex – the needle cap on the prefilled syringe contains dry natural rubber (derived from latex); have kidney problems; are pregnant or plan to become pregnant. It is not known if Neulasta® may harm your unborn baby; are breastfeeding or plan to breastfeed. It is not known if Neulasta® passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.



Strong chemotherapy puts your body at risk for infection that can disrupt your cancer treatments.

Chemotherapy works by killing fast-growing cancer cells. One of the side effects of chemotherapy is that it can decrease the number of white blood cells in your body. Having a low white blood cell count can weaken your immune system, which increases your risk of infection.

About febrile neutropenia and how it can derail your cancer treatment

A low white blood cell count is called neutropenia. When combined with a fever, it's called febrile neutropenia (FN)—and it may be a sign that you have an infection, which is one of the most serious side effects of strong chemotherapy. In fact, based on a study of patient data from 2007-2010, more than 80% of US patients with febrile neutropenia require hospitalization.



How Neulasta® Works

Pegfilgrastim is a common white blood cell booster, or a granulocyte colony-stimulating factor (G-CSF) injection, which is prescribed to prevent febrile neutropenia (FN). Neulasta® is the #1 prescribed brand of pegfilgrastim. Only Neulasta® offers Onpro®, an on-body injector designed to automatically deliver your Neulasta® at the right time.*

Next-day Neulasta® reduced the incidence of FN by 94% and FN-related hospitalizations by 93%.


A study of 928 patients with breast cancer showed that when given once every chemotherapy cycle, Neulasta® helped protect against the risk of infection and reduced hospitalizations. 17% of patients got infections when not treated with Neulasta®—while only 1% of patients got infections when treated with Neulasta®, a 94% reduction. 14% of patients were hospitalized when not treated with Neulasta®—while only 1% of patients treated with Neulasta® were hospitalized, a 93% reduction.





in FN-related hospitalizations

Please read the additional Important Safety Information on pages 30-31.



Using next-day Neulasta® from your very first cycle of chemo

A study of patients with different types of cancer showed that more patients who received Neulasta® stayed on their chemotherapy regimen than patients who did not receive a white blood cell booster.



Neulasta® Onpro® can help ensure that you stay on track with your chemotherapy regimen

Important Safety Information

What are the possible serious side effects of Neulasta®?

Spleen Rupture. Your spleen may become enlarged and can rupture while taking Neulasta®. A ruptured spleen can cause death. Call your healthcare provider right away if you have pain in the left upper stomach area or left shoulder tip area.

^{*}If, for any reason, you believe you did not receive your full dose of Neulasta® or that your on-body injector is not working correctly, immediately contact your healthcare provider, as an incomplete dose could increase infection risk.





~1 million patients have used Neulasta® Onpro®

Only Neulasta® Onpro® reduces the risk of febrile neutropenia without having to go back to the doctor's office.

Today with Neulasta® Onpro®, most patients can spend the day after strong chemotherapy at home—where they can also reduce their risk of coming into contact with viral infections. Also, it is hard for some patients to return to their physician the next day to receive Neulasta®. Missing a dose of Neulasta® can increase your risk of febrile neutropenia.



95% of patients would choose Onpro® again

Before your first round of strong chemo, ask your doctor if Neulasta® Onpro® can be part of your treatment plan.

Important Safety Information

A serious lung problem called Acute Respiratory
Distress Syndrome (ARDS). Call your healthcare provider or
get emergency medical help right away if you have shortness
of breath with or without a fever, trouble breathing, or a fast
rate of breathing.

Neulasta® Onpro® May Be Able to Help With Common Challenges

For many patients, there's no place like home the day after chemo. There's no reason to make trips back to the doctor's office if you can stay at home instead. Ask your doctor if Neulasta® Onpro® is right for you.

Neulasta® Onpro® may be right for you if you:

- Are an adult
- Are comfortable with the patient instructions for use
- Have no allergies to acrylics



*If, for any reason, you believe you did not receive your full dose of Neulasta® or that your on-body injector is not working correctly, immediately contact your healthcare provider, as an incomplete dose could increase infection risk.

Important Safety Information

Serious Allergic Reactions. Neulasta® can cause serious allergic reactions. These reactions can cause a rash over your whole body, shortness of breath, wheezing, dizziness, swelling around your mouth or eyes, fast heart rate and sweating.

Please see pages 28-29 for additional important information.

Please read the additional Important Safety Information on pages 30-31.

10

When You're on Chemo, Dates Can Be Important

We are pleased to provide you with this calendar. We hope you will find it a helpful tool in keeping track of important information, including:



DATES OF DOCTOR VISITS



CHEMO AND LAB APPOINTMENTS



RESULTS OF YOUR BLOOD COUNTS



SYMPTOMS YOU MAY BE FEELING



Mark your chemo dates on this calendar and reflect on your day at home

January 2021

S	М	Т	W	Т	F	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
31						

March 2021

S	M	Т	W	Т	F	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30	31			

May 2021

S	М	Т	W	Т	F	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31					

July 2021

S	M	Т	W	Т	F	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

September 2021

S	M	Т	W	Т	F	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30		

November 2021

S	M	Т	W	Т	F	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30				

February 2021

S	M	Т	W	Т	F	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28						

April 2021

S	M	Т	W	Т	F	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	

June 2021

S	М	Т	W	Т	F	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30			

August 2021

S	M	Т	W	Т	F	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31				

October 2021


S	M	Т	W	Т	F	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
31						

December 2021

S	M	Т	W	Т	F	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31	

Your Neulasta® Onpro® Device

Right after your strong chemotherapy treatment, your healthcare provider will apply the on-body injector (OBI) to your skin. The OBI is designed to automatically deliver your Neulasta® dose over 45 minutes, approximately 27 hours after activation. Once your dose is complete, remove the injector and dispose of it as instructed in the Patient Instructions for Use.



The summary does not replace the Patient Instructions for Use. If you are using Neulasta® Onpro®, it's important that you review the Patient Instructions, and call your doctor if you have any questions.



Flashing green: OBI is working properly.

Solid green (or turned off):

Medication delivery should be complete. Check to see if the fill indicator reads "empty" and there is no noticeably wet adhesive.

Flashing red: OBI error—call your healthcare provider immediately.

Remember: When OBI beeps, check the status light.

Status Light

Adhesive Pad

The pad attaches the OBI directly to the skin on the back of your arm or abdomen.

Fill Indicator


The black line should be at FULL until the OBI starts delivering your dose of Neulasta®. The black line should be at EMPTY when your Neulasta® delivery is complete.

Important Information

While the on-body injector (OBI) is in place you should avoid:

- Traveling, driving or operating heavy machinery during hour 26 through hour 29 after the OBI is applied
- Sleeping on the OBI or applying pressure on the OBI. The OBI may not work properly.
- Bumping the OBI or knocking it off your body

Please see pages 28-29 for additional important information.



What to expect when using Neulasta® Onpro®

This information is a summary and does not replace the Patient Instructions for Use. It's important that you thoroughly review the Patient Instructions for Use. These instructions cover everything you need to know about the on-body injector (OBI). If you have any questions, please contact your healthcare provider.



16


For a more secure fit, an adhesive extender that fits around the on-body injector called a PodPal™ may be added by your doctor or nurse if they deem it appropriate.

Important Safety Information

If you have an allergic reaction during the delivery of Neulasta®, remove the on-body-injector for Neulasta® by grabbing the edge of the adhesive pad and peeling off the on-body-injector. Get emergency medical help right away.

At the doctor's office

On the same day of your chemo, your healthcare provider will prepare an area of your skin and apply the OBI.



Applying the on-body injector (OBI)

As your doctor places the OBI on your skin, you will hear beeps as the amber status light changes to green—which means the cannula is inserted.

Once your doctor confirms that the OBI is properly applied to your skin, you can go home.

For the next 27 hours, the green light will flash every 5 seconds (which means the OBI is working properly).

Important Safety Information

Sickle Cell Crises. You may have a serious sickle cell crisis, which could lead to death, if you have a sickle cell disorder and receive Neulasta®.



Do all you can to reduce the risk of infection.

During strong chemotherapy, you may be at risk for infection. There may be ways you can help protect yourself.

Here are some things you can do:

- Wash your hands frequently with soap and water. This is especially important after you use the toilet and before cooking and eating.
- Avoid people who have diseases—such as colds or the flu that you can catch
- Clean cuts and scrapes right away with warm water and soap.
 Cover with a bandage. Ask your doctor and care team if using antibiotic creams is right for you.
- Avoid crowds where germs can be rampant
- Be careful not to cut or nick yourself. Use an electric shaver instead of a razor. Wear protective gloves when gardening or cleaning to avoid cuts and scrapes.

Look out for signs of infection.

It's very important to tell your doctor or nurse if you experience any of the following:

- Fever
- Any new area of redness, tenderness, or swelling
- Pus or yellowish discharge from an injury or other location
- New cough or shortness of breath
- New abdominal (belly) pain
- Shaking chills that may be followed by sweating
- Burning or pain when passing urine
- Sore throat
- Sores or white patches in the mouth

Important Safety Information

Kidney injury (glomerulonephritis). Neulasta® can cause kidney injury. Call your healthcare provider right away if you develop any of the following symptoms: swelling of your face or ankles, blood in your urine or dark colored urine, or you urinate less than usual.



Any questions? Ask your doctor.

It's important that you feel free to talk with your doctor or nurse about your treatment at any time. Asking questions can go a long way toward helping clear up any confusion you may have.

And because another set of ears can be helpful, you may want to bring a friend or family member to doctor appointments.

The following are some questions you may want to ask:

- What type of chemotherapy am I receiving?
- Am I at risk for infection?
- What could happen if I get a serious infection?
- Should Neulasta® be part of my treatment plan?
- How long will I have to use Neulasta[®]?
- Is Neulasta® Onpro® an option for me?
- Does my insurance cover Neulasta® or Neulasta® Onpro®?


Order your FREE disposal container today

Visit Neulasta.com/Support

Important Safety Information

Increased white blood cell count (leukocytosis). Your healthcare provider will check your blood during treatment with Neulasta®.

Overview For Using Neulasta® Onpro®



It is important that you thoroughly review the Patient Instructions For Use. These instructions cover everything you need to know about the on-body injector (OBI). The information in this brochure does not replace the Patient Instructions For Use. Please contact your healthcare provider if you have any questions.

What to expect at home

While wearing Neulasta® Onpro® at home, you'll need to do a few things.

Check the light, listen for beeps: Check the status light occasionally to make sure it flashes green. Your OBI will beep when it needs your attention.

If the light flashes red, call your healthcare provider immediately.

On the day of delivery

- 1. Mark your calendar: Know when your Neulasta® delivery is expected to start. A caregiver should be with you the first time you receive Neulasta® with the OBI. If the OBI is on the back of your arm, always have a caregiver with you to monitor the OBI.
- **2. Listen for 3 beeps:** You will hear a series of 3 beeps—and the light will flash green—when dose delivery is about to begin.
- **3. Listen for 1 long beep:** Once dose delivery is complete, you will hear one long beep and the light will turn solid green (or the light will turn off).
- **4. Confirm dose delivery:** The black line on your OBI fill indicator will be on empty after your dose delivery is complete.
- 5. Remove OBI and dispose: Slowly peel off the OBI, and use the free Sharps Disposal Container Program to help you easily and safely dispose of the OBI.

To order your FREE disposal container, call 1-844-MYNEULASTA or visit Neulasta.com/Support

Important Information

Keep the OBI at least 4 inches away from electrical equipment such as cellphones, cordless telephones, microwaves and other common appliances. If the OBI is too close to electrical equipment, it may not work correctly and can lead to a missed or incomplete dose of Neulasta®.

Please see pages 28-29 for additional important information.

Please read the additional Important Safety Information on pages 30-31.

22

Let Us Show You How You May Be Covered

If you are eligible and commercially insured*

The Amgen FIRST STEP™ program can help cover your out-of-pocket prescription costs, including deductible, co-insurance, and co-payment.

- \$0 out of pocket for first dose or cycle
- **\$5 out of pocket** for subsequent doses or cycles, up to the brand program benefit maximum
- No income eligibility requirement

If you have government insurance like Medicare

We can refer you to independent nonprofit patient assistance programs that may be able to help you afford the co-pay cost of your medicine.[†]

If you are uninsured

The Amgen Safety Net Foundation is a nonprofit patient assistance program sponsored by Amgen that helps qualifying patients access Amgen medicines at no cost.

*Terms, conditions, and program maximums apply. This program is not open to patients receiving prescription reimbursement under any federal-, state-, or government-funded healthcare program. Not valid where prohibited by law.

†Resources include referrals to independent nonprofit patient assistance programs. Eligibility for resources provided by independent nonprofit patient assistance programs.

CALL TODAY!

1-888-4ASSIST (1-888-427-7478) Monday through Friday, 9 am to 8 pm ET or visit AmgenAssist360.Com/Enroll



We're here for you and your loved ones.

Assistance designed to support you throughout your treatment journey so you can focus on what's most important to you.

Single point of contact through our Nurse Ambassadors

Amgen Nurse Ambassadors provide a single point of contact who can help you find the resources that are most important to you.* Let our nurses provide personal support related to your financial coverage and referrals to resources that may help your emotional wellness. We're here to help!

Financial support options for any insurance type

Whatever type of insurance you have—even if you have none—we can help you understand how your Amgen medicine may be covered and refer you to programs that may be able to help you afford it.*

Referrals to resources for day-to-day living

We can refer you to independent nonprofit organizations that may provide you with community resources, one-on-one counseling services, and local support groups.

Medication answers

Have questions about your Amgen medication? We can help you get the answers you need.

*Provided through independent nonprofit patient assistance programs; program eligibility is based on the nonprofit's criteria. Amgen has no control over these programs and provides referrals as a courtesy only.

†Patients should always talk to their healthcare provider about any medical decisions or concerns they may have.

Paying for Neulasta® Onpro®

Amgen is committed to helping ensure you will be able to get Neulasta® Onpro® at an affordable cost.

The majority of commercial and Medicare plans cover Neulasta® and Neulasta® Onpro®.



With commercial insurance, 85% of Neulasta® prescriptions cost patients **\$5 or less per dose.***

The remaining 15% of Neulasta® prescriptions cost patients an average of \$697 per dose.*



With Medicare Advantage, 62% of Neulasta® prescriptions cost \$5 or less per dose.*

The remaining 38% of Neulasta® prescriptions cost patients an average of \$748 per dose.*



With Medicare Part B, 46% of Neulasta® prescriptions cost patients **\$5 or less per dose.***

The remaining 54% of Neulasta® prescriptions cost patients an average of \$908 per dose.*

Patients with traditional Medicare (Part B) may also carry supplemental insurance, such as Medigap. 99% of Neulasta® prescriptions for patients with Medicare coverage and supplemental insurance (such as Medigap) cost, on average, less than \$2 per dose. The remaining 1% of prescriptions cost patients an average of \$268 per dose.*




With Medicaid, 99% of Neulasta® prescriptions cost **\$0 per dose.***

The remaining 1% of Neulasta® prescriptions cost patients an average of \$615 per dose.*

*These data are based on paid claims data from national data providers for the period 1/1/2018—12/31/2018. Your actual cost may vary depending on your dose, insurance coverage, and eligibility for support programs. Talk to your insurance provider for specific information about your prescription coverage.

Amgen Safety Net Foundation for Patients in Need

The Amgen Safety Net Foundation supports uninsured patients and certain underinsured patients who do not have coverage for their Amgen medication and have a financial need. Qualifying uninsured patients must not be eligible for Medicaid, Medicare, or any other financial support options. The Amgen Safety Net Foundation may be able to provide Neulasta® at no cost to eligible patients.



- See the Instructions for Use for the on-body injector (OBI) for information about the OBI
 - Know the time that delivery of your dose of Neulasta® is expected to start
 - Avoid traveling, driving, or operating heavy machinery during hour 26 through hour 29 after the OBI is applied.
 Avoid activities and places that may interfere with monitoring during the 45-minute period that Neulasta® is expected to be delivered by the OBI, and for 1 hour after delivery.
- A caregiver should be with you the first time that you receive Neulasta® with the OBI
- If placed on the back of the arm, a caregiver must be available to monitor the status of the OBI
- If you have an allergic reaction during the delivery of Neulasta®, remove the OBI by grabbing the edge of the adhesive pad and peeling off the OBI. Get emergency medical help right away.
- You should only receive a dose of Neulasta® on the day your healthcare provider tells you
- You should not receive your dose of Neulasta® any sooner than 24 hours after you finish receiving your chemotherapy. The OBI is programmed to deliver your dose about 27 hours after your healthcare provider places the OBI on your skin.

- Do not expose the OBI to the following because the OBI may be damaged and you could be injured:
 - Diagnostic imaging (eg, CT scan, MRI, Ultrasound, X-ray)
 - Radiation treatment
 - Oxygen rich environments, such as hyperbaric chambers
- Avoid airport X-ray scans. Request a manual pat down instead.
 Use care during a manual pat down to help prevent the OBI from being accidentally removed.
- Keep the OBI at least 4 inches away from electrical equipment such as cell phones, cordless telephones, microwaves and other common appliances. If the OBI is too close to electrical equipment, it may not work correctly and can lead to a missed or incomplete dose of Neulasta®.
- The OBI is for adult patients only
- If your OBI is not working properly, you may miss your dose or you
 may not receive your full dose of Neulasta®. If you miss your dose
 or do not receive your full dose of Neulasta®, you may have an
 increased risk of developing fever or infection.
- Call your healthcare provider right away, as you may need a replacement dose, if any of the following occur:
 - OBI for Neulasta® comes off before or during a dose delivery.
 Do not re-apply it.
 - OBI for Neulasta® is leaking
 - Adhesive on your OBI for Neulasta® becomes noticeably wet (saturated) with fluid, or there is dripping. This may mean that Neulasta® is leaking out of your OBI for Neulasta®. If this happens you may only receive some of your dose of Neulasta®, or you may not receive a dose at all.
 - OBI for Neulasta® status light is flashing red

Please review the Patient Instructions for Use for instructions and information about the on-body injector (OBI). Discuss any questions you have with your healthcare provider. The information in this guide is intended as a summary. It is not intended to replace any instructions from your healthcare provider or the Instructions For Use which came packaged with the on-body injector (OBI).

Please read additional Important Safety Information on pages 30-31.

29

Important Safety Information

Do not take Neulasta® if you have had a serious allergic reaction to pegfilgrastim or filgrastim.

Before you receive Neulasta®, tell your healthcare provider about all of your healthcare conditions, including if you:

- Have a sickle cell disorder
- Have had severe skin reaction to acrylic adhesives
- Are allergic to latex The needle cap on the prefilled syringe contains dry natural rubber (derived from latex).
- Have kidney problems
- Are pregnant or plan to become pregnant. It is not known if Neulasta® may harm your unborn baby.
- Are breastfeeding or plan to breastfeed. It is not known if Neulasta® passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible serious side effects of Neulasta®?

- Spleen Rupture. Your spleen may become enlarged and can rupture while taking Neulasta®. A ruptured spleen can cause death. Call your healthcare provider right away if you have pain in the left upper stomach area or left shoulder tip area.
- A serious lung problem called Acute Respiratory Distress Syndrome (ARDS). Call your healthcare provider or get emergency medical help right away if you have shortness of breath with or without a fever, trouble breathing, or a fast rate of breathing.
- Serious Allergic Reactions. Neulasta® can cause serious allergic reactions. These reactions can cause a rash over your whole body, shortness of breath, wheezing, dizziness, swelling around your mouth or eyes, fast heart rate and sweating.

If you have an allergic reaction during the delivery of Neulasta®, remove the on-body-injector for Neulasta® by grabbing the edge of the adhesive pad and peeling off the on-body-injector. Get emergency medical help right away.

- Sickle Cell Crises. You may have a serious sickle cell crisis, which could lead to death, if you have a sickle cell disorder and receive Neulasta®.
- Kidney injury (glomerulonephritis). Neulasta® can cause kidney injury. Call your healthcare provider right away if you develop any of the following symptoms: swelling of your face or ankles, blood in your urine or dark colored urine, or you urinate less than usual.
- Increased white blood cell count (leukocytosis). Your healthcare provider will check your blood during treatment with Neulasta®.

- Decreased platelet count (thrombocytopenia). Your healthcare provider will check your blood during treatment with Neulasta[®]. Tell your healthcare provider if you have unusual bleeding or bruising during treatment with Neulasta®. This could be a sign of decreased platelet counts, which may reduce the ability of your blood to clot.
- Capillary Leak Syndrome. Neulasta® can cause fluid to leak from blood vessels into your body's tissues. This condition is called "Capillary Leak Syndrome" (CLS). CLS can quickly cause you to have symptoms that may become life-threatening. Get emergency medical help right away if you develop any of the following symptoms:
 - Swelling or puffiness and are urinating less than usual
 - Trouble breathing
 - Swelling of your stomach area (abdomen) and feeling of fullness
 - Dizziness or feeling faint
 - A general feeling of tiredness
- Myelodysplastic syndrome and acute myeloid leukemia. If you have breast cancer or lung cancer, when Neulasta® is used with chemotherapy and radiation therapy, or with radiation therapy alone, you may have an increased risk of developing a precancerous blood condition called myelodysplastic syndrome (MDS) or a blood cancer called acute myeloid leukemia (AML). Symptoms may include tiredness, fever, and easy bruising or bleeding. Call your healthcare provider if you develop these symptoms during treatment with Neulasta®.
- Inflammation of the aorta (aortitis). Inflammation of the aorta (the large blood vessel which transports blood from the heart to the body) has been reported in patients who received Neulasta[®]. Symptoms may include fever, abdominal pain, feeling tired, and back pain. Call your healthcare provider if you experience these symptoms.

The most common side effect of Neulasta® is pain in your bones and in your arms and legs.

These are not all the possible side effects of Neulasta®. Call your healthcare provider for medical advice about side effects. You may report negative side effects to the FDA at 1-800-FDA-1088.

Please see Neulasta® Patient Information.

Neulasta® Injection: 6 mg/0.6 mL in a single-dose prefilled syringe for manual use only.

Neulasta® Injection: 6 mg/0.6 mL in a single-dose prefilled syringe co-packaged with the on-body-injector (OBI) for Neulasta® (Neulasta® Onpro® kit).

Neulasta® is given as an injection under the skin (subcutaneous).

31

neulasta.com



For more information, please visit Neulasta.com

One Amgen Center Drive Thousand Oaks, CA 91320-1799 www.amgen.com

